f Mitochondrial Dysfunction in MASLD: Unveiling Mechanisms and Optimizing Therapeutic Strategies

References

1. YanaiH. AdachiH. HakoshimaM. IidaS. KatsuyamaH. Metabolic-dysfunction-associated steatotic liver disease—its pathophysiology, association with atherosclerosis and cardiovascular disease, and treatments.Int. J. Mol. Sci.202324201547310.3390/ijms24201547337895151
   [Google Scholar]
2. ChanW. Metabolic dysfunction-associated steatotic liver disease: A state-of-the-art review.J. Obes. Metab. Syndr.202332319721310.7570/jomes2305237700494
   [Google Scholar]
3. JorgačevićB. VučevićD. SamardžićJ. MladenovićD. VeskovićM. VukićevićD. JešićR. RadosavljevićT. The effect of CB1 antagonism on hepatic oxidative/nitrosative stress and inflammation in nonalcoholic fatty liver disease.Curr. Med. Chem.202028116918010.2174/092986732766620030312273432124686
   [Google Scholar]
4. RamanathanR. AliA.H. IbdahJ.A. Mitochondrial dysfunction plays central role in nonalcoholic fatty liver disease.Int. J. Mol. Sci.20222313728010.3390/ijms2313728035806284
   [Google Scholar]
5. FDA approves first treatment for patients with liver scarring due to fatty liver disease. U.S. Food and Drug Administration.Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-patients-liver-scarring-due-fatty-liver-disease (accessed 2024-05-21).
6. ZineldeenD.H. TahoonN.M. SarhanN.I. AICAR ameliorates non-alcoholic fatty liver disease via modulation of the HGF/NF-κB/SNARK signaling pathway and restores mitochondrial and endoplasmic reticular impairments in high-fat diet-fed rats.Int. J. Mol. Sci.2023244336710.3390/ijms2404336736834782
   [Google Scholar]
7. MyintM. OppedisanoF. De GiorgiV. KimB.M. MarincolaF.M. AlterH.J. NesciS. Inflammatory signaling in NASH driven by hepatocyte mitochondrial dysfunctions.J. Transl. Med.202321175710.1186/s12967‑023‑04627‑037884933
   [Google Scholar]
8. ColcaJ.R. McDonaldW.G. CaveyG.S. ColeS.L. HolewaD.D. Brightwell-ConradA.S. WolfeC.L. WheelerJ.S. CoulterK.R. KilkuskieP.M. GrachevaE. KorshunovaY. TrusgnichM. KarrR. WileyS.E. DivakaruniA.S. MurphyA.N. VigueiraP.A. FinckB.N. KletzienR.F. Identification of a mitochondrial target of thiazolidinedione insulin sensitizers (mTOT)--relationship to newly identified mitochondrial pyruvate carrier proteins.PLoS One201385e6155110.1371/journal.pone.006155123690925
   [Google Scholar]
9. FujisawaK. NishikawaT. KukidomeD. ImotoK. YamashiroT. MotoshimaH. MatsumuraT. ArakiE. TZDs reduce mitochondrial ROS production and enhance mitochondrial biogenesis.Biochem. Biophys. Res. Commun.20093791434810.1016/j.bbrc.2008.11.14119084501
   [Google Scholar]
10. ZhangZ. ZhangX. MengL. GongM. LiJ. ShiW. QiuJ. YangY. ZhaoJ. SuoY. LiangX. WangX. TseG. JiangN. LiG. ZhaoY. LiuT. Pioglitazone inhibits diabetes-induced atrial mitochondrial oxidative stress and improves mitochondrial biogenesis, dynamics, and function through the PPAR-γ/PGC-1α signaling pathway.Front. Pharmacol.20211265836210.3389/fphar.2021.65836234194324
    [Google Scholar]
11. CoronaJ.C. DuchenM.R. PPARγ as a therapeutic target to rescue mitochondrial function in neurological disease.Free Radic. Biol. Med.201610015316310.1016/j.freeradbiomed.2016.06.02327352979
    [Google Scholar]
12. DongY. ZhuangX.X. WangY.T. TanJ. FengD. LiM. ZhongQ. SongZ. ShenH.M. FangE.F. LuJ.H. Chemical mitophagy modulators: Drug development strategies and novel regulatory mechanisms.Pharmacol. Res.202319410683510.1016/j.phrs.2023.10683537348691
    [Google Scholar]
13. LaMoiaT.E. ShulmanG.I. Cellular and molecular mechanisms of metformin action.Endocr. Rev.2021421779610.1210/endrev/bnaa02332897388
    [Google Scholar]
14. DuX. ZengQ. LuoY. HeL. ZhaoY. LiN. HanC. ZhangG. LiuW. Application research of novel peptide mitochondrial-targeted antioxidant SS-31 in mitigating mitochondrial dysfunction.Mitochondrion20247510184610.1016/j.mito.2024.10184638237649
    [Google Scholar]
15. NewmanN.J. Yu-Wai-ManP. SubramanianP.S. MosterM.L. WangA.G. DonahueS.P. LeroyB.P. CarelliV. BiousseV. Vignal-ClermontC. SergottR.C. SadunA.A. Rebolleda FernándezG. ChwaliszB.K. BanikR. BazinF. RouxM. CoxE.D. TaielM. SahelJ.A. GiuliaA. ShwetaA. RudraniB. PieroB. ValérieB. HayleyB. AsmaB. MicheleC. ValerioC. CeliaC. Hui-ChenC. SteveC. ChwaliszB.K. ManuelaC. PietroD.A. DeBuskA.A. JulieD.Z. JannahD. DonahueS.P. LindrethD.B. SimonaE. AlcidesF.F. ElizabethF. SapnaG. DeborahG. FrançoisG.J. RabihH. HallerJ.A. GadH. George BakerH.I.I.I. Jeong-MinH. LaiaJ.U. NeringaJ. RustumK. WahibaK. La ChiaraM. LeroyB.P. MariaM. MarcM. MemonM.A. SusanM. MosterM.L. Muñoz NegreteF.J. NewmanN.J. GhazalaO.K. ShrijiP. PaulaP. PeragalloJ.H. LiseP. MaryP. GemaR.F. MartinaR. SadunA.A. José-AlainS. MelissaS.M. SergottR.C. SubramanianP.S. ChuanbinS. KatyT. HeatherT. IrenaT. TuckerW.R. CatherineV-C. An-GuorW. SaigeW. PatrickY-W-M. LHON REFLECT Study Group Randomized trial of bilateral gene therapy injection for m.11778G>A MT-ND4 Leber optic neuropathy.Brain202314641328134110.1093/brain/awac42136350566
    [Google Scholar]